Roberto Spogli PhD (M), [ORCID ID: 0000-0001-7188-8543] was born in 1977 in Perugia, Italy. He received his PhD in pharmaceutical chemistry from the University of Perugia in 2005 and his MS in chemistry from the University of Perugia in 2001. In 2005, he was a lecturer at the Department of Pharmacy of the University of Perugia, giving lectures in the official course 'Biotechnology of Pharmaceuticals', and worked as a researcher at the University of Perugia—Department of Pharmacy. In 2006, he joined the private sector as a researcher at the pharmaceutical company Dompé Pharma. In 2008, he cofounded and managed Prolabin & Tefarm, a former spin-off company of the University of Perugia—now an innovative SME—where he currently works. Dott Spogli has 22 years of experience in chemical synthesis, functionalization chemistry and characterization of materials and nanomaterials, composite systems and drug delivery, specializing in technology transfer from TRL 3 to TRL 8 in various industrial fields. His work is documented by several international publications and patents as well as innovative products developed and commercialized by Prolabin.
Roberto Spogli PhD (M), [ORCID ID: 0000-0001-7188-8543] was born in 1977 in Perugia, Italy. He received his PhD in pharmaceutical chemistry from the University of Perugia in 2005 and his MS in chemistry from the University of Perugia in 2001. In 2005, he was a lecturer at the Department of Pharmacy of the University of Perugia, giving lectures in the official course 'Biotechnology of Pharmaceuticals', and worked as a researcher at the University of Perugia—Department of Pharmacy. In 2006, he joined the private sector as a researcher at the pharmaceutical company Dompé Pharma. In 2008, he cofounded and managed Prolabin & Tefarm, a former spin-off company of the University of Perugia—now an innovative SME—where he currently works. Dott Spogli has 22 years of experience in chemical synthesis, functionalization chemistry and characterization of materials and nanomaterials, composite systems and drug delivery, specializing in technology transfer from TRL 3 to TRL 8 in various industrial fields. His work is documented by several international publications and patents as well as innovative products developed and commercialized by Prolabin.